Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy
RNH Seervai, WC Cho, EY Chu… - Journal of cutaneous …, 2022 - Wiley Online Library
Background Advances in molecular biology and genetics have contributed to breakthrough
treatments directed at specific pathways associated with the development of cancer. Small …
treatments directed at specific pathways associated with the development of cancer. Small …
Synthesis of Polysubstituted Pyrroles by the Reaction of Enaminoketones, Arylglyoxals, and N,N-Dimethylbarbituric Acid
NN Kolos, NV Chechina - Chemistry of Heterocyclic Compounds, 2019 - Springer
Novel pentasubstituted pyrroles containing a propanoic acid fragment in position 1 were
obtained by the reaction of arylglyoxals, N, N dimethylbarbituric and 3-[(4-oxopent-2-en-2-yl) …
obtained by the reaction of arylglyoxals, N, N dimethylbarbituric and 3-[(4-oxopent-2-en-2-yl) …
Cutaneous Manifestation of Chemotherapeutic Agents
CR Agrawal, K Domadia, S Kothiwal - Complications of Cancer Therapy …, 2024 - Springer
Cutaneous toxicities are commonly encountered in patients receiving systemic therapy.
Development of targeted anti cancer agents and their use over conventional therapy is not …
Development of targeted anti cancer agents and their use over conventional therapy is not …
СИНТЕЗ ПОЛИЗАМЕЩЕННЫХ ПИРРОЛОВ ВЗАИМОДЕЙСТВИЕМ ЕНАМИНОКЕТОНОВ, АРИЛГЛИОКСАЛЕЙ И N,N-ДИМЕТИЛБАРБИТУРОВОЙ КИСЛОТЫ
НН Колос, НВ Чечина - Chemistry of Heterocyclic Compounds, 2019 - 5.179.29.131
Новые пентазамещенные пирролы, содержащие фрагмент пропaновой кислоты в
положении 1, получены реакцией арилглиоксалей, N, N-диметилбарбитуровой и 3-[(4 …
положении 1, получены реакцией арилглиоксалей, N, N-диметилбарбитуровой и 3-[(4 …
Eyebrow Whitening Induced by Imatinib
I Yavasoglu, A Turgutkaya… - International Journal of …, 2020 - journals.lww.com
Sir, Imatinib is a proven tyrosine kinase inhibitor (TKI) widely used for the treatment of
chronic myeloid leukemia (CML). It is a rationally designed oral signal transduction inhibitor …
chronic myeloid leukemia (CML). It is a rationally designed oral signal transduction inhibitor …
[PDF][PDF] Odbarwienie włosów jako powikłanie leczenia sunitynibem–opis przypadku Hair discoloration as an adverse effect of therapy with sunitinib–a case report
K Sobańska, Z Synowiec, R Ramlau, E Grześkowiak - akademiamedycyny.pl
Sunitynib jest inhibitorem licznych kinaz tyrozynowych o działaniu antyangiogennym i
przeciwnowotworowym, stosowanym w pierwszej linii leczenia zaawansowanego raka …
przeciwnowotworowym, stosowanym w pierwszej linii leczenia zaawansowanego raka …